Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for most solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

Bristol Myers Squibb (BMY) is one of the stocks most ... Over the past month, shares of this biopharmaceutical company have returned -6.5%, compared to the Zacks S&P 500 composite's -2% change.

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and ...

As a leading biopharmaceutical company, Bristol Myers Squibb recognizes that its responsibility extends well beyond the discovery, development, and delivery of innovative medicines. BMS’ ESG strategy ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.